Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
News Jun 07, 2012
Evotec AG has announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 4.0 million to Evotec.
The milestone was for the transition of a respiratory programme into pre-clinical development.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This is the sixteenth milestone achieved as part of our alliance with Boehringer Ingelheim and represents an important transition of this programme into pre-clinical development. The alliance continues to achieve significant scientific and commercial success, reflecting the truly collaborative efforts of teams from Evotec and Boehringer Ingelheim.”
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018